Galecto, INC 10-Q quarterly reports

Damora Therapeutics, Inc. (DMRA) filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased R&D and G&A expenses, substantial cash reserves, and ongoing development of its mutCALR-targeting therapies.

Damora Therapeutics, Inc. reported its first quarter 2026 financial results, highlighting significant increases in research and development expenses and a substantial cash position following recent financings, while advancing its mutCALR-targeting drug candidates.

Galecto, Inc. reported a reduced net loss for Q3 and 9M 2025 but faces substantial doubt about its ability to continue as a going concern due to insufficient cash to fund operations beyond the next 12 months.

Galecto, Inc. reported a significantly reduced net loss for Q2 2025 and the first half of the year, driven by lower operating expenses, but disclosed substantial doubt about its ability to continue as a going concern without additional funding.

Galecto, Inc. announces its Q1 2025 financial results, highlighting a strategic focus on oncology and liver diseases with the development of GB3226 and GB1211.

Galecto, Inc. announced its Q3 2024 financial results and a strategic shift to focus on developing GB1211 and BRM-1420 after completing a strategic alternative review.

Galecto, Inc. announced its second quarter 2024 financial results, highlighting reduced operating expenses due to restructuring and ongoing strategic alternative exploration.

Galecto, Inc. announced its first quarter 2024 financial results, highlighting a significant decrease in research and development expenses as the company explores strategic alternatives.